Latest News

Latest News

Clinical Trial Results 30 October 2026

Clinical Trial Results 30 October 2026

Clinical trial results 30 October 2026: head and neck cancer, small cell lung cancer, type 2 diabetes and breast cancer. Genmab’s petosemtamab plus pembrolizumab met both co-primary endpoints in first-line PD-L1-positive head and neck cancer. Amgen’s tarlatamab plus...

read more
Retatrutide vs Ozempic: How Do They Compare in Diabetes?

Retatrutide vs Ozempic: How Do They Compare in Diabetes?

Retatrutide vs Ozempic now has a head-to-head answer in type 2 diabetes. In an 80-week phase 3 trial, retatrutide lowered A1C by 2.2 percentage points, against 1.8 for Ozempic 2 mg. Body weight fell by 19.5 to 20.9 per cent on retatrutide and 9.4 per cent on Ozempic....

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Twin B7-H3 ADC Wins in Seoul Leave the UK Route Unresolved

Twin B7-H3 ADC Wins in Seoul Leave the UK Route Unresolved

Two B7-H3 ADC readouts landed in the same Seoul session on 13 September 2026. Both reported a survival win in relapsed small cell lung cancer. Both trials ran entirely in China. Neither dataset, on its own, is a filing package for the FDA, the EMA or the MHRA. Two...

read more
Weekly News Roundup | 14 September 2026

Weekly News Roundup | 14 September 2026

Life science news 14 September 2026: two US approvals for rare diseases, a landmark antibody-drug conjugate readout, and two UK moves on pharmacy access and AI oversight. Scholar Rock’s Isembyld won FDA approval, described by the agency as the first SMA therapy to...

read more
Clinical Trials Roundup | 11 Sept 2026

Clinical Trials Roundup | 11 Sept 2026

Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...

read more
The Other Half of Innovation

The Other Half of Innovation

What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...

read more
Twin B7-H3 ADC Wins in Seoul Leave the UK Route Unresolved

Twin B7-H3 ADC Wins in Seoul Leave the UK Route Unresolved

Two B7-H3 ADC readouts landed in the same Seoul session on 13 September 2026. Both reported a survival win in relapsed small cell lung cancer. Both trials ran entirely in China. Neither dataset, on its own, is a filing package for the FDA, the EMA or the MHRA. Two...

read more
Weekly News Roundup | 14 September 2026

Weekly News Roundup | 14 September 2026

Life science news 14 September 2026: two US approvals for rare diseases, a landmark antibody-drug conjugate readout, and two UK moves on pharmacy access and AI oversight. Scholar Rock’s Isembyld won FDA approval, described by the agency as the first SMA therapy to...

read more
Clinical Trials Roundup | 11 Sept 2026

Clinical Trials Roundup | 11 Sept 2026

Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...

read more
The Other Half of Innovation

The Other Half of Innovation

What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Section 232 Pharma Tariffs: What Changes on 29 September

Section 232 Pharma Tariffs: What Changes on 29 September

On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...

read more
CBD Vaping: When Product Innovation Outpaces the Science

CBD Vaping: When Product Innovation Outpaces the Science

Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...

read more
Neurodegeneration Pipeline 2026: Genetic Medicine Leads

Neurodegeneration Pipeline 2026: Genetic Medicine Leads

Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...

read more
The Future of Collagen Hydrogels in Regenerative Medicine

The Future of Collagen Hydrogels in Regenerative Medicine

Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...

read more

Further News

When Familiar Is Not Documented: Mandatory GRAS and Traditional Botanicals

Longan was a familiar food in the home I grew up in. It was a tasty summer fruit we ate in southern China, much like an American family might think of mango. Years later, when I started making beverages in St. Louis, I used longan in a hydration drink, well before FDA...

Medicine Does Not Run on Blood Alone

Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...

ALK7 Obesity Drugs: Who Is Developing Them After Roche’s Rona Deal?

Several companies are now developing ALK7 obesity drugs, but human data remain early. On 13 October 2026, Rona Therapeutics licensed an ALK7-targeting RNAi candidate to Roche. Arrowhead, and SiranBio with GSK, have also disclosed ALK7 programmes. Fierce Biotech...

What Pharma Can Learn From Retail as GLP-1 Demand Reshapes Healthcare

Demand for weight-loss medicines in the UK has run well ahead of what the NHS can provide. Researchers at UCL estimate that 1.6 million adults in Great Britain used a medicine to lose weight between early 2024 and early 2025, and that a further 3.3 million were...

Admilparant Approval: What the ALOFT-IPF Result Shows So Far

Admilparant approval for idiopathic pulmonary fibrosis (IPF) is not yet decided, and LSDN found no announced regulatory filing. On 12 October 2026, Bristol Myers Squibb (BMS) reported that its phase 3 ALOFT-IPF trial met its primary endpoint. That was at the 60 mg...

AI Can Accelerate Optimisation, But It Cannot Replace Biological Discovery

Artificial intelligence is increasingly being integrated into the drug discovery process. From the identification of therapeutic targets to the prediction of molecular interactions and ranking of compounds to be developed further, the power of computational tools...

Why Women’s Health Innovation Needs Commercialisation Strategy

Women’s health innovation is experiencing a period of rapid growth. Founders are developing new diagnostics, medical devices, digital platforms, wearables and therapies for conditions that have historically received too little research attention and investment. That...

A Regulatory Playbook for SaMD and Digital Health

Six decisions that shape FDA readiness for software as a medical device and connected digital health products A software team can build a compelling product and still reach the submission stage with a fundamental problem: the evidence supports a narrower claim than...

Beyond Binding: Functional Prediction in GPCR Drug Discovery

In GPCR drug discovery, as elsewhere, teams know the cost of getting early decisions wrong. A corrected JAMA analysis of 63 new drugs and biologics approved by the US Food and Drug Administration between 2009 and 2018 estimated the median capitalised R&D...

An AI Mental Health App Is Not a Therapist: How to Build One Honestly

It's 3am. Thoughts are racing in circles, and there is no one to talk to: friends are asleep, the next appointment with a psychotherapist is weeks away, and not everyone can afford one. So a person either lies awake, scrolls endlessly through social media, or turns to...

Weekly News Roundup | 12 October 2026

Life science news 12 October 2026: three deals, three US approvals and two UK regulatory updates. Shionogi agreed to buy IntraBio for $2bn. Viatris offered $1.65bn for Pacira BioSciences. The FDA approved Tecentriq for Stage III dMMR colon cancer. Shionogi will...

Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

The FDA approved atezolizumab for dMMR colon cancer on 8 October 2026. NICE has set no date, and LSDN found no UK licence yet.

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.